Show simple item record

dc.contributor.authorShah, M
dc.contributor.authorLorigan, Paul C
dc.contributor.authorO’Brien, M
dc.contributor.authorFossella, F
dc.contributor.authorMoore, K
dc.contributor.authorBhatia, S
dc.contributor.authorKirby, M
dc.contributor.authorWoll, P
dc.date.accessioned2016-04-01T10:06:54Zen
dc.date.available2016-04-01T10:06:54Zen
dc.date.issued2016-03-09en
dc.identifier.citationPhase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors 2016 Investigational New Drugsen
dc.identifier.issn0167-6997en
dc.identifier.issn1573-0646en
dc.identifier.doi10.1007/s10637-016-0336-9en
dc.identifier.urihttp://hdl.handle.net/10541/604182en
dc.relation.urlhttp://link.springer.com/10.1007/s10637-016-0336-9en
dc.rightsArchived with thanks to Investigational New Drugsen
dc.titlePhase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.en
dc.typeArticleen
dc.contributor.departmentOhio State University College of Medicine, Columbus, OH, 43210en
dc.identifier.journalInvestigational New Drugsen


This item appears in the following Collection(s)

Show simple item record